$EVMN News

UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress

Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301

Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?

Evommune Consensus Price Target Decreased by 13.25% to $24.48

This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On

Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

Evommune Halts Atopic Dermatitis Program Following Trial Failure

RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

Why Is EVMN Stock Down 13% After-Hours?

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Evommune Reveals Top-Line Results From EVO756 Phase 2b Trial In Moderate-To-Severe Atopic Dermatitis; Says Trial Did Not Meet The Primary Endpoint Of Percent Change In Eczema Area And Severity Index Score From Baseline At Week 12; EVO756 Was Generally Well Tolerated; To Continue Phase 2b Development Of EVO756 In Migraine Prophylaxis; Will Not Advance EVO756 In Atopic Dermatitis

Evommune (EVMN) Price Target Decreased by 10.03% to 28.22

Needham Initiates Coverage of Evommune (EVMN) with Buy Recommendation

Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights